Diagnostic and Clinical Utility of Novel Anti-PAD4 Antibodies in Anti-CCP2-Negative and Anti-CCP2-Positive Rheumatoid Arthritis
Diagnostics · 01.11.2026 · 16 (21) · 3615
DOI: 10.3390/diagnostics16213615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 01.11.2026. Verfasst von Tyler O'Malley und 4 weiteren Autor:innen. Beteiligte Einrichtung: Exagen, Inc., Vista, CA 92081, USA. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Diagnosis of rheumatoid arthritis (RA) remains challenging, particularly in anti-CCP2-negative disease. Novel biomarkers, including anti-peptidyl arginine deiminase 4 (PAD4) autoantibodies, have emerged as promising tools for improving diagnostic accuracy in RA patients. The aim of this study was to analyze the performance of the first clinically validated anti-PAD4 assay.
Methods
A total of 192 well-characterized RA patients and 383 controls were included in this study and tested for anti-CCP2, RF IgA, and RF IgM (all Phadia, Thermo Fisher) as well as anti-PAD4 IgA and anti-PAD4 IgG by ELISA (laboratory developed test, Exagen, Inc., Vista, CA, USA). Results for the anti-PAD4 IgG ELISA for 143 patients were used for method comparison with a particle-based multi-analyte technology (PMAT, Inova Diagnostics, San Diego, CA, USA).
Results
ELISA and PMAT showed moderate-to-good agreement for anti-PAD4 IgG (rho = 0.66; Passing–Bablok slope 0.83, 95% CI 0.71–0.92; kappa = 0.67). Anti-PAD4 IgG was significantly correlated with anti-PAD4 IgA (rho = 0.47) and weakly correlated with RF IgM (rho = 0.29), RF IgA (rho = 0.28), and anti-CCP2 (rho = 0.22) (all p < 0.001). The PAD4 IgG and IgA ELISAs were validated in the RA population, yielding sensitivities/specificities of 31.8%/92.7% for anti-PAD4 IgG, 18.8%/93.7% for anti-PAD4 IgA, 43.2%/91.1% for RF IgM, 23.4%/96.1% for RF IgA, and 42.2%/99.2% for anti-CCP2, respectively. Anti-CCP2 IgG achieved the highest discriminatory performance (AUC = 0.86), followed by RF IgA (AUC = 0.69) and RF IgM (AUC = 0.67). Anti-PAD4 IgG and anti-PAD4 IgA showed modest discrimination (AUC = 0.55 and 0.52, respectively). Among the biomarkers evaluated, anti-CCP2 demonstrated the strongest association with RA (OR = 110.27), followed by RF IgM (OR = 7.40), RF IgA (OR = 7.14), anti-PAD4 IgG (OR = 5.92), and anti-PAD4 IgA (OR = 3.48) (all q < 0.001). In the anti-CCP2-negative population, the strongest association was found for anti-PAD4 IgG (OR = 2.87, q = 0.005), followed by RF IgM (OR = 2.20, p = 0.024). After adjustment for anti-CCP2, RF, age, and sex, anti-PAD4 IgG remained independently associated with RA (OR = 2.69, p = 0.003), with a small gain in discrimination (ΔAUC = 0.02–0.04).
Conclusions
Our study established comparability between methods and shows that anti-PAD4 provides modest but statistically significant diagnostic information in the anti-CCP2-negative RA population, independent of anti-CCP2 and RF, in the anti-CCP2-negative RA population, where conventional markers are uninformative.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Exagen, Inc., Vista, CA 92081, USA.
ORCID-Profile: Michael Mahler
Zitieren
APA
O'Malley, T., Partain, B., Alvarez, C., Nagle, C., & Mahler, M. (2026). Diagnostic and Clinical Utility of Novel Anti-PAD4 Antibodies in Anti-CCP2-Negative and Anti-CCP2-Positive Rheumatoid Arthritis. Diagnostics, 16(21), 3615. https://doi.org/10.3390/diagnostics16213615
Vancouver
O'Malley T, Partain B, Alvarez C, Nagle C, Mahler M. Diagnostic and Clinical Utility of Novel Anti-PAD4 Antibodies in Anti-CCP2-Negative and Anti-CCP2-Positive Rheumatoid Arthritis. Diagnostics. 2026;16(21):3615. doi:10.3390/diagnostics16213615
BibTeX
@article{OMalley2026,
author = {O'Malley, Tyler and Partain, Brittany and Alvarez, Cynthia and Nagle, Clayton and Mahler, Michael},
title = {Diagnostic and Clinical Utility of Novel Anti-PAD4 Antibodies in Anti-CCP2-Negative and Anti-CCP2-Positive Rheumatoid Arthritis},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {21},
pages = {3615},
doi = {10.3390/diagnostics16213615}
}
EUVIMED